Please assess the completion status of the following clinical trial:

Trial Title: A Study of Clofarabine for Older Patients With Newly Diagnosed Acute Myelogenous Leukemia (AML) (CLASSIC II)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of AML (de novo, secondary or with an antecedent hematologic disorder \[AHD\])~* Age ≥ 60 years~* Eastern Cooperative Oncology Group (ECOG) performance status 0-2~* Presence of at least one adverse prognostic factor: Age ≥ 70 years; or AHD; or ECOG performance status of 2; or Intermediate or unfavorable (i.e., adverse) karyotype defined as any cytogenetic profile except the presence of any of the following:~  * t(8;21)(q22;q22)~ * inv(16)(p13;q22 or t(16;16)(p13;q22)~ * t(15;17)(q22;q12) and variants.~* Adequate renal and hepatic function: Total bilirubin ≤ 1.5 x upper limit of normal (ULN); Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN; and Serum creatinine ≤ 1.0 mg/dL; if serum creatinine \> 1.0 mg/dL, then the estimated glomerular filtration rate (GFR) must be \> 60 mL/min/1.73 m\^2 as calculated by the Modification of Diet in Renal Disease (MDRD) equation~* Adequate cardiac function: left ventricular ejection fraction (LVEF) ≥ 40% or left ventricular fractional shortening ≥ 22%~Exclusion Criteria:~* Diagnosis of acute promyelocytic leukemia~* Prior treatment with clofarabine~* Prior treatment for AML or an antecedent hematologic disorder~* Prior hematopoietic stem cell transplant (HSCT)~* Prior radiation therapy to the pelvis~* Investigational agent received within 30 days prior to the first dose of study drug~* Ongoing uncontrolled systemic infection~* Diagnosis of another malignancy, unless the patient has been disease-free for at least 5 years following the completion of curative intent therapy with the following exceptions: Patients with treated non-melanoma skin cancer, in-situ carcinoma or cervical intraepithelial neoplasia regardless of disease-free duration are eligible for this study if definitive treatment for the condition has been completed; Patients with organ-confined prostate cancer with no evidence of recurrent or progressive disease based on PSA value are eligible for this study if hormonal therapy has been initiated or a radical prostatectomy has been performed~* Clinical evidence of central nervous system (CNS) involvement~* Severe concurrent medical condition or psychiatric disorder that would preclude study participation~* Positive human immunodeficiency virus (HIV) test

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Clofarabine (Type: EXPERIMENTAL): Participants received an induction cycle of clofarabine 30 mg/m\^2/day intravenous infusion for 5 consecutive days. Participants could then receive up to 5 additional cycles, repeated minimally every 28 days, of clofarabine 20 mg/m\^2/day intravenous infusion for 5 consecutive days.

Based on this trial design, predict the completion outcome and termination type (if applicable).